middle.news
Argenica Advances Phase 2b Stroke Trial With AI and Regulatory Wins
8:54am on Wednesday 29th of April, 2026 AEST
•
Biotechnology
Read Story
Argenica Advances Phase 2b Stroke Trial With AI and Regulatory Wins
8:54am on Wednesday 29th of April, 2026 AEST
Key Points
Phase 2b trial design incorporates AI-enabled patient selection
Scaled manufacturing underway with Corden Pharma
EMA grants full paediatric waiver, easing EU regulatory path
Received $4 million R&D tax refund and $0.5 million grant
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE